<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity dstore:dataset="ifcwbg-in" dstore:index="191" hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-45102</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Medgenome Project</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">The proposed equity financing is for Medgenome Inc. (Medgenome or the Company), Indias leading genetic diagnostics, research and data licensing player. Founded in 2013, MedGenome is a genomics and clinical data driven diagnostics and research company with a focus on next generation sequencing (NGS). It is leading genetic diagnostics player in India with a footprint across South Asia and is set to expand its operations into other geographies. Company is headquartered in Foster City, California and has a state-of-the-art, College of American Pathology (CAP) certified lab and research center in Bangalore, India.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Expected development impact includes: (i) Access to genetic diagnostic services and targeted medication (ii) Market creation by significantly deepening the genomic segment via demonstration and replication, and capacity building channels.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">MEDGENOME INC.</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-45102" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="1"></activity-status>
  <activity-date iso-date="2021-05-18" type="1"></activity-date>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Medgenome Inc.  Govind Ramakrishnan  MedGenome Corporate  080-67111211  govind.ramakrishnan@medgenome.com  3rd Floor, Narayana Netralaya building, Narayana Health City, #258/A, Bommasandra, Bangalore, 560099, India  Websitehttps://diagnostics.medgenome.com/https://research.medgenome.com/</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">0  0  0  0  0  0  0  0  0.0000         MedGenome Labs Limited.      3rd Floor, Narayana   Netralaya   building, Narayana Health City, #258/A, Bommasandra, Bangalore, 560099, India</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="IN" percentage="100">
   <narrative xml:lang="EN">India</narrative>
  </recipient-country>
  <location ref="IN-India">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">Medgenome Inc. is registered in Delaware, USA and has an Indian subsidiary with office in Bangalore, India. It currently provides research services to clients in USA and genetic diagnostics tests in India</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>22.0000000000 79.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">other</narrative>
  </sector>
  <tag code="COVID-19" vocabulary="99"></tag>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetail/SII/45102">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetail/SII/45102">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
